JP2019511212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511212A5 JP2019511212A5 JP2018544355A JP2018544355A JP2019511212A5 JP 2019511212 A5 JP2019511212 A5 JP 2019511212A5 JP 2018544355 A JP2018544355 A JP 2018544355A JP 2018544355 A JP2018544355 A JP 2018544355A JP 2019511212 A5 JP2019511212 A5 JP 2019511212A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- sequence
- cancer
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 4
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108010048507 poliovirus receptor Proteins 0.000 claims 4
- 102100029740 Poliovirus receptor Human genes 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 101150069255 KLRC1 gene Proteins 0.000 claims 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 229940126546 immune checkpoint molecule Drugs 0.000 claims 1
- 102000027596 immune receptors Human genes 0.000 claims 1
- 108091008915 immune receptors Proteins 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301727P | 2016-03-01 | 2016-03-01 | |
| US62/301,727 | 2016-03-01 | ||
| US201662364924P | 2016-07-21 | 2016-07-21 | |
| US62/364,924 | 2016-07-21 | ||
| PCT/IL2017/050256 WO2017149538A1 (en) | 2016-03-01 | 2017-02-28 | Antibodies specific to human poliovirus receptor (pvr) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511212A JP2019511212A (ja) | 2019-04-25 |
| JP2019511212A5 true JP2019511212A5 (enExample) | 2020-04-09 |
| JP6966176B2 JP6966176B2 (ja) | 2021-11-10 |
Family
ID=58410405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544355A Active JP6966176B2 (ja) | 2016-03-01 | 2017-02-28 | ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10906987B2 (enExample) |
| EP (2) | EP4043492A1 (enExample) |
| JP (1) | JP6966176B2 (enExample) |
| KR (2) | KR20250065434A (enExample) |
| CN (1) | CN109071666B (enExample) |
| AU (2) | AU2017228055B2 (enExample) |
| CA (1) | CA3015619A1 (enExample) |
| CO (1) | CO2018010538A2 (enExample) |
| ES (1) | ES2903280T3 (enExample) |
| IL (2) | IL296874A (enExample) |
| MX (2) | MX2018010445A (enExample) |
| RU (1) | RU2756275C2 (enExample) |
| SG (1) | SG11201807437XA (enExample) |
| WO (1) | WO2017149538A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11098130B1 (en) | 2015-08-03 | 2021-08-24 | Tasrif Pharmaceutical, LLC | Antibodies and antibody fragments against the CD155 receptor and methods of use thereof |
| US20220056146A1 (en) * | 2015-08-03 | 2022-02-24 | Tasrif Pharmaceutical, LLC | Antibodies and Antigen Binding Fragments Against CD155 Methods of Use Thereof |
| KR20250065434A (ko) | 2016-03-01 | 2025-05-12 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체 |
| WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| WO2019102456A1 (en) | 2017-11-27 | 2019-05-31 | University Of Rijeka Faculty Of Medicine | Immunotoxins for treating cancer |
| WO2019215728A1 (en) | 2018-05-09 | 2019-11-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human nectin4 |
| BR112021003156A2 (pt) | 2018-08-23 | 2021-05-11 | Seagen, Inc. | composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit. |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| AU2019328575B2 (en) | 2018-08-30 | 2024-07-11 | Immunitybio, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| JP7397874B2 (ja) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| JP7606706B2 (ja) | 2019-01-13 | 2024-12-26 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | ヒトネクチン－２に特異的な抗体 |
| WO2020257639A1 (en) | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| EP4041392A1 (en) * | 2019-10-08 | 2022-08-17 | Nectin Therapeutics Ltd. | Antibodies against the poliovirus receptor (pvr) and uses thereof |
| KR102370915B1 (ko) | 2019-10-22 | 2022-03-08 | 단국대학교 천안캠퍼스 산학협력단 | 폴리오바이러스를 검출하기 위한 등온증폭 반응용 프라이머 세트 및 이의 용도 |
| CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| US12187763B2 (en) | 2020-02-11 | 2025-01-07 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| AU2021220196A1 (en) | 2020-02-11 | 2022-08-04 | HCW Biologics, Inc. | Methods of activating regulatory T cells |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4157460A1 (en) | 2020-06-01 | 2023-04-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| CN112538108B (zh) * | 2020-12-24 | 2022-06-28 | 郑州大学 | 高亲和pvr突变体 |
| WO2023022729A1 (en) * | 2021-08-20 | 2023-02-23 | Tasrif Pharmaceutical, LLC | Antibodies and antigen binding fragments against cd155 methods of use thereof |
| CN114005538B (zh) * | 2021-11-30 | 2025-10-28 | 中国医科大学附属第一医院 | Nectin家族和类nectin分子在低级别胶质瘤预后模型中的应用 |
| CN119451983A (zh) | 2022-02-28 | 2025-02-14 | 耐科廷疗法有限公司 | 针对连接蛋白2的人源化抗体及其药物偶联物 |
| WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
| AU2023236289A1 (en) | 2022-03-15 | 2024-08-15 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| CN119384289A (zh) | 2022-04-13 | 2025-01-28 | 免疫生物公司 | 用于治疗神经炎症性障碍的多链嵌合多肽 |
| JP2025529266A (ja) | 2022-09-04 | 2025-09-04 | ネクチン セラピューティクス リミテッド | ヒト化抗ｐｖｒ抗体の薬物複合体 |
| CN116284395B (zh) * | 2022-12-12 | 2024-11-08 | 合肥天港免疫药物有限公司 | 抗cd155的抗体及其应用 |
| WO2024233945A1 (en) * | 2023-05-10 | 2024-11-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy of polio virus receptor inhibitors and fucose |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| KR102669477B1 (ko) * | 2023-09-04 | 2024-06-10 | 재단법인 아산사회복지재단 | 신규 항-pvr 항체 또는 이의 항원 결합 단편, 및 이의 용도 |
| CN118359711B (zh) * | 2024-06-20 | 2024-10-15 | 华淞(上海)生物医药科技有限公司 | 一种抗脊髓灰质炎病毒1型抗体及其制备方法和用途 |
| WO2026043909A1 (en) | 2024-08-19 | 2026-02-26 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| WO2026043906A1 (en) | 2024-08-19 | 2026-02-26 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| ES2102007T3 (es) | 1992-01-23 | 1997-07-16 | Merck Patent Gmbh | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. |
| AU687010B2 (en) | 1992-07-17 | 1998-02-19 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| WO1995003832A1 (en) | 1993-07-30 | 1995-02-09 | Thomas Jefferson University | Intracellular immunization |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| ATE274064T1 (de) | 1995-05-23 | 2004-09-15 | Morphosys Ag | Multimere proteine |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| US6264940B1 (en) * | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
| US6518033B1 (en) * | 1998-08-05 | 2003-02-11 | The Research Foundation Of State University Of New York | Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment |
| US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| JP4619651B2 (ja) | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| EP1481993A1 (en) * | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| JP2008544746A (ja) | 2005-05-12 | 2008-12-11 | ザイモジェネティクス， インコーポレイテッド | 免疫応答を調節するための組成物および方法 |
| WO2007016285A2 (en) | 2005-07-28 | 2007-02-08 | Novartis Ag | M-csf specific monoclonal antibody and uses thereof |
| HUE039865T2 (hu) | 2005-12-20 | 2019-02-28 | Sbi Biotech Co Ltd | Anti-ILT7 antitest |
| AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| FR2909092B1 (fr) * | 2006-11-24 | 2012-10-19 | Pf Medicament | Nouveaux anticorps anti-proliferation |
| KR101123487B1 (ko) | 2007-03-20 | 2012-03-23 | 일라이 릴리 앤드 캄파니 | 항?스클레로스틴 항체 |
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP5686361B2 (ja) * | 2010-01-28 | 2015-03-18 | 国立大学法人 筑波大学 | 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法 |
| TWI655210B (zh) | 2010-12-08 | 2019-04-01 | 艾伯維史坦森特瑞斯有限責任公司 | 新穎調節劑及其使用方法 |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| JP6185463B2 (ja) | 2011-07-15 | 2017-08-23 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｒｓｐｏ結合剤およびその使用法 |
| KR101502501B1 (ko) | 2011-12-27 | 2015-03-13 | 주식회사 엘지화학 | 리튬 이차전지 및 그 제조방법 |
| CA2875980A1 (en) | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
| AU2013355379B2 (en) | 2012-12-04 | 2018-08-09 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| MX2015010682A (es) | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Nuevos conjugados de anticuerpos y usos de los mismos. |
| TWI888366B (zh) | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
| RU2016111137A (ru) | 2013-08-28 | 2017-10-03 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Сконструированные конъюгаты против dll3 и способы применения |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| EP3119211A1 (en) | 2014-03-18 | 2017-01-25 | Gokmen, Vural | A solution for extending shelf life of ready-to-eat fresh fruits and/or vegetables and an application method thereof |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| KR20250065434A (ko) | 2016-03-01 | 2025-05-12 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체 |
-
2017
- 2017-02-28 KR KR1020257014225A patent/KR20250065434A/ko active Pending
- 2017-02-28 JP JP2018544355A patent/JP6966176B2/ja active Active
- 2017-02-28 IL IL296874A patent/IL296874A/en unknown
- 2017-02-28 US US16/081,667 patent/US10906987B2/en active Active
- 2017-02-28 SG SG11201807437XA patent/SG11201807437XA/en unknown
- 2017-02-28 AU AU2017228055A patent/AU2017228055B2/en active Active
- 2017-02-28 WO PCT/IL2017/050256 patent/WO2017149538A1/en not_active Ceased
- 2017-02-28 CA CA3015619A patent/CA3015619A1/en active Pending
- 2017-02-28 ES ES17713469T patent/ES2903280T3/es active Active
- 2017-02-28 IL IL261200A patent/IL261200B2/en unknown
- 2017-02-28 RU RU2018134065A patent/RU2756275C2/ru active
- 2017-02-28 EP EP21200696.9A patent/EP4043492A1/en active Pending
- 2017-02-28 MX MX2018010445A patent/MX2018010445A/es unknown
- 2017-02-28 KR KR1020187028157A patent/KR102812377B1/ko active Active
- 2017-02-28 EP EP17713469.9A patent/EP3423495B1/en active Active
- 2017-02-28 CN CN201780027236.6A patent/CN109071666B/zh active Active
-
2018
- 2018-08-29 MX MX2022014867A patent/MX2022014867A/es unknown
- 2018-10-01 CO CONC2018/0010538A patent/CO2018010538A2/es unknown
-
2020
- 2020-12-10 US US17/118,062 patent/US20210115150A1/en not_active Abandoned
-
2023
- 2023-08-15 US US18/450,022 patent/US20240018257A1/en active Pending
-
2024
- 2024-03-25 AU AU2024201912A patent/AU2024201912A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522801A5 (enExample) | ||
| US11103579B2 (en) | Combination of DR5 agonist and anti-PD-1 antagonist and methods of use | |
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| JP2018532383A5 (enExample) | ||
| CN107428832B (zh) | 抗pd-l1抗体 | |
| JP2022541435A5 (enExample) | ||
| KR102838340B1 (ko) | 다중-특이적 항체 및 이들의 제조 및 사용 방법 | |
| US20230357407A1 (en) | Bispecific anti pd1-anti tim3 antibodies | |
| JP2021522801A (ja) | ヒトネクチン４に特異的な抗体 | |
| JP2020501531A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| CN108348521A (zh) | 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺 | |
| JP2021524478A5 (enExample) | ||
| JP2020512973A5 (enExample) | ||
| JP2022519341A5 (enExample) | ||
| JP2020528765A5 (enExample) | ||
| JP2021520201A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| AU2025259843A1 (en) | 4-1BB Binding Protein And Application Thereof | |
| CA3070290A1 (en) | Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody | |
| CN111393529A (zh) | 与ox40l非竞争结合的抗ox40抗体 | |
| EP4132568A1 (en) | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections | |
| JP2021501575A (ja) | 二重特異性抗体並びにその製造方法及び使用方法 |